Regenacy Pharmaceuticals is developing a novel, disease-modifying approach to treating peripheral neuropathies that goes beyond pain and symptom management to restore peripheral nerve function. Our lead compound ricolinostat (ACY-1215) is an oral, selective inhibitor of the microtubule modifying enzyme HDAC6 with first-in-class potential, currently positioned to enter Phase 2 clinical trials. Our investigation of ricolinostat for diabetic, chemotherapy-induced and inherited peripheral neuropathies is based on compelling proof-of-concept preclinical studies demonstrating restoration of normal nerve function. We were founded in December 2016 following the acquisition of Acetylon Pharmaceuticals by Celgene. Regenacy received exclusive rights to ricolinostat, a clinical stage, orally bioavailable, HDAC6 selective inhibitor, for a range of non-cancer disease indications. We also have a unique and proprietary portfolio of selective HDAC1,2 inhibitors with potential for treating cancer, hemoglobinopathies, and cognitive dysfunction.
View Top Employees from Regenacy Pharmaceuticals, Inc.Website | http://www.regenacy.com |
Revenue | $5.2 million |
Employees | 9 (7 on RocketReach) |
Founded | 2016 |
Address | 303 Wyman St, Waltham, Massachusetts 02451, US |
Phone | (617) 415-5030 |
Technologies |
JavaScript,
HTML,
Twitter
+11 more
(view full list)
|
Industry | Biotechnology, Pharmaceuticals, Healthcare, Science and Engineering, Therapeutics, Health Care |
Competitors | Araim Pharmaceuticals, Inc., Centrexion Therapeutics Corp., Dracen Pharmaceuticals, Inc., eXIthera Pharmaceuticals Inc |
SIC | SIC Code 28 Companies, SIC Code 283 Companies |
NAICS | NAICS Code 32541 Companies, NAICS Code 3254 Companies, NAICS Code 325 Companies, NAICS Code 32 Companies |
Looking for a particular Regenacy Pharmaceuticals, Inc. employee's phone or email?
The Regenacy Pharmaceuticals, Inc. annual revenue was $5.2 million in 2024.
John Rocha is the CFO of Regenacy Pharmaceuticals, Inc..
7 people are employed at Regenacy Pharmaceuticals, Inc..
Regenacy Pharmaceuticals, Inc. is based in Waltham, Massachusetts.
The NAICS codes for Regenacy Pharmaceuticals, Inc. are [32541, 3254, 325, 32].
The SIC codes for Regenacy Pharmaceuticals, Inc. are [28, 283].